ODYY - Odyssey Health rises 11% on completing phase 1 trial of concussion treatment
- Odyssey Health ( OTCPK:ODYY ) said it had completed the study of all cohorts for its Phase I Single Ascending Dosing and Multiple Ascending Dosing clinical trial of PRV-002, its drug to treat concussion.
- ( OTCPK:ODYY ) is up ~11% .
- The company said it is working with the United States military to identify sites for the Phase II trials. Concussions in the armed forces are a serious issue.
For further details see:
Odyssey Health rises 11% on completing phase 1 trial of concussion treatment